Formulation Development, Evaluation and Profound Biological Activity of Polyherbal Gel containing Vigna radiate, <i>Aloe barbidenis</i> and <i>Moringa oleifera</i> DOI
Muhammad Tajammal Khan,

Simranjeet,

Sofia Pasi

и другие.

International Journal of Newgen Research in Pharmacy & Healthcare, Год журнала: 2024, Номер unknown, С. 142 - 148

Опубликована: Дек. 31, 2024

This drug delivery system is designed to deliver a therapeutic amount of medicine the right place in body, allowing for rapid achievement and maintenance desired concentrations. Gels are solids or semisolids that include at least two substances; typically, they composed dense mass surrounded permeated by liquid. A number chemical components present, including organic acids, flavonoids, phenolic acids. Because its anti-inflammatory, antibacterial, antioxidant characteristics, Vigna radiata an effective acne treatment. Cosmetically ubiquitous Aloe barbadensis (Aloe Vera) has long been known efficacy alleviating skin conditions pigmentation, acne, burns, more. anti-inflammatory wound-healing it useful ingredient prescription treatments. In fact, there wide spectrum medicines available treatment from conventional antibiotics more contemporary methods even natural cures. Mixing gel with ethanolic extracts Moringa oleifera resulted improved carbopol base; this trio herbal may help reduce acne. The antimicrobial inquiry did not find any signs microbial contamination zone inhibition. vivo irritation examination detect lesions such defatting, unpleasant reactions, local systemic alteration.

Язык: Английский

Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance DOI Creative Commons
Zhipeng Wang, Jie Wang,

Dengxiong Li

и другие.

Journal of Pharmaceutical Analysis, Год журнала: 2025, Номер unknown, С. 101232 - 101232

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

2
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches DOI Open Access
Adam Khorasanchi, Feng Hong, Yuanquan Yang

и другие.

Cancer Drug Resistance, Год журнала: 2025, Номер unknown

Опубликована: Фев. 19, 2025

Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers uniquely comprehensive and integrative perspective on these pathways, systematically examining both androgen receptor (AR)-dependent factors (including AR overexpression, point mutations, glucocorticoid signaling, splice variants, post-translational modifications, altered coregulators, intratumoral hormone biosynthesis) AR-independent pathways (such as neuroendocrine differentiation, lineage plasticity, alternative growth factor signaling). We also highlight influencing immunotherapy, chemotherapy, radiopharmaceutical therapy targeted therapy. By synthesizing emerging insights across domains, this not only clarifies the underlying biology mCRPC but identifies key leverage points for more effective interventions. Building foundation, we propose forward-looking framework overcoming drug resistance, emphasizing importance biomarker-guided patient selection, combination strategies that simultaneously target multiple mechanisms, novel therapies under investigation. These recommendations are intended to guide future clinical trial designs research priorities move beyond incremental improvements. Ultimately, synthesis aims serve resource clinicians researchers accelerate development durable, precision-based treatment mCRPC.

Язык: Английский

Процитировано

1
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease DOI Creative Commons

Qiuzhi Zhou,

Weixia Wang, Chunchu Deng

и другие.

Molecular Neurobiology, Год журнала: 2025, Номер unknown

Опубликована: Март 25, 2025

Язык: Английский

Процитировано

1
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer DOI Creative Commons
Yulu Zhang,

Annan Ming,

Junyan Wang

и другие.

Pharmacological Research, Год журнала: 2024, Номер 205, С. 107234 - 107234

Опубликована: Май 28, 2024

After the initial androgen deprivation therapy (ADT), part of prostate cancer may continuously deteriorate into castration-resistant (CRPC). The majority patients suffer from localized illness at primary diagnosis that could rapidly assault other organs. This disease stage is referred as metastatic (mCRPC). Surgery and radiation are still treatment CRPC, but have some adverse effects such urinary symptoms sexual dysfunction. Hormonal castration interfering receptor (AR) signaling pathway indispensable for most advanced patients, first- second-generation novel AR inhibitors effectively cure hormone sensitive (HSPC). However, resistance to these chemical agents inevitable many experience relapses. inhibitor mainly involves mutation, splice variant formation amplification, which indicates important role in CRPC. Proteolysis-targeting chimera (PROTAC), a potent technique degrade targeted protein, has recently undergone extensive development biological tool therapeutic drug. potential become next generation antitumor therapeutics it overcome shortcomings conventional small molecule inhibitors. In this review, we summarize molecular mechanisms on PROTACs targeting hoping provide insights drug clinical medication.

Язык: Английский

Процитировано

9
Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation DOI Creative Commons
Shareef Shaik,

Prasanna Kumar Reddy Gayam,

Manish Chaudhary

и другие.

Bioorganic Chemistry, Год журнала: 2024, Номер 153, С. 107868 - 107868

Опубликована: Окт. 4, 2024

Язык: Английский

Процитировано

5
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies DOI Open Access
Jingsong Zhang, Juskaran Chadha

Cancers, Год журнала: 2024, Номер 16(17), С. 3098 - 3098

Опубликована: Сен. 6, 2024

There is an unmet need to develop new treatments for metastatic prostate cancer. With the development of targeted radioligand therapies, bispecific T cell engagers, antibody-drug conjugates and chimeric antigen receptor (CAR T) tumor-associated surface antigens have emerged as therapeutic targets in Ongoing completed clinical trials targeting prostate-specific membrane (PSMA), six transmembrane epithelial 1 (STEAP1), kallikrein-related peptidase 2 (KLK2), stem (PSCA), delta-like protein 3 (DLL3) cancer were reviewed. Strategies sequential or combinational therapy discussed.

Язык: Английский

Процитировано

4
Razing the Scaffolding: The Elimination of Non-Catalytic Functions of Kinases through Targeted Protein Degradation DOI
Sarah Pogash, Steven Fletcher

RSC Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Overexpression and activation of kinases often results in cancer initiation progression through both catalytic non-catalytic functions by promoting rapid proliferation, growth, survival, metastasis cells. Catalytic functions...

Язык: Английский

Процитировано

0
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity DOI
Arun Azad, Howard Gurney, Craig Underhill

и другие.

Investigational New Drugs, Год журнала: 2025, Номер unknown

Опубликована: Апрель 28, 2025

Язык: Английский

Процитировано

0
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers DOI Creative Commons
Whi‐An Kwon, Jae Young Joung

Biomolecules, Год журнала: 2025, Номер 15(5), С. 625 - 625

Опубликована: Апрель 27, 2025

Metastatic prostate cancer (mPCa) remains a significant cause of cancer-related mortality in men. Advances molecular profiling have demonstrated that the androgen receptor (AR) axis, DNA damage repair pathways, and PI3K/AKT/mTOR pathway are critical drivers disease progression therapeutic resistance. Despite established benefits hormone therapy, chemotherapy, bone-targeting agents, mPCa commonly becomes treatment-resistant. Recent breakthroughs highlighted importance identifying actionable genetic alterations, such as BRCA2 or ATM defects, render tumors sensitive to poly-ADP ribose polymerase (PARP) inhibitors. Parallel efforts refined imaging—particularly prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography—to detect localize metastatic lesions with high sensitivity, thereby guiding patient selection for PSMA-targeted radioligand therapies. Multi-omics innovations, including liquid biopsy technologies, enable real-time tracking emergent AR splice variants reversion mutations, supporting adaptive therapy paradigms. Nonetheless, complexity necessitates combination strategies, pairing inhibition PI3K/AKT blockade PARP inhibitors, inhibit tumor plasticity. Immuno-oncological approaches remain challenging unselected patients; however, subsets mismatch deficiency neuroendocrine phenotypes may benefit from immune checkpoint targeted epigenetic interventions. We present these pivotal advances, discuss how biomarker-guided integrative treatments can improve management.

Язык: Английский

Процитировано

0
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium DOI Creative Commons

Justus Simon Israel,

Laura-Maria Marcelin,

Christian Thomas

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Июль 17, 2024

Continued exploration of the androgen receptor (AR) is crucial, as it plays pivotal roles in diverse diseases such prostate cancer (PCa), serving a significant therapeutic focus. Therefore, Department Urology Dresden hosted an international meeting for scientists and clinical oncologists to discuss newest advances AR research. The 2nd International Androgen Receptor Symposium was held Dresden, Saxony, Germany, from 26-27.04.2024, organised by Dr. Holger H.H. Erb. Following format first meeting, more than 35 8 countries attended event recent developments, research challenges, identification venues An important new feature involvement PhD students young investigators, acknowledging high scientific quality their work. symposium included three covers: research, basic translational novel strategies target AR. Moreover, based on its increasing relevance, PSMA theranostic mini-symposium added at end allow audience theranostic. This report focuses highlights discussions meeting.

Язык: Английский

Процитировано

2